FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085657245> ?p ?o ?g. }

• W3085657245 endingPage "4437" @default.
• W3085657245 startingPage "4430" @default.
• W3085657245 abstract "Abstract Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of epigenetic therapy with panobinostat and decitabine after allo-HSCT and before donor lymphocyte infusion (DLI) in poor-risk patients with acute myeloid leukemia (AML) or refractory anemia with excess blasts with International Prognostic Scoring System score ≥1.5. A total of 140 poor-risk patients with AML aged 18 to 70 years were registered, and 110 proceeded to allo-HSCT. Three dose levels were evaluated for dose-limiting toxicities, including panobinostat monotherapy 20 mg at days 1, 4, 8, and 11 of a 4-week cycle (PNB mono group) and panobinostat combined with either decitabine 20 mg/m2 (PNB/DAC20 group) or decitabine 10 mg/m2 (PNB/DAC10 group) at days 1 to 3 of every 4-week cycle. After phase 1, the study continued as phase 2, focusing on completion of protocol treatment and treatment outcome. PNB mono and PNB/DAC10 were feasible, whereas PNB/DAC20 was not related to prolonged cytopenia. Sixty of 110 patients who underwent transplantation were eligible to receive their first DLI within 115 days after allo-HSCT. Grade 3 and 4 adverse events related to panobinostat and decitabine were observed in 23 (26%) of the 87 patients, and they received epigenetic therapy. Cumulative incidence of relapse was 35% (standard error [SE] 5), and overall survival and progression-free survival at 24 months were 50% (SE 5) and 49% (SE 5). Post–allo-HSCT epigenetic therapy with panobinostat alone or in combination with low-dose decitabine is feasible and is associated with a relatively low relapse rate. The trial was registered at the European Clinical Trial Registry, https://www.clinicaltrialsregister.eu, as ECT2012-003344-74." @default.
• W3085657245 created "2020-09-21" @default.
• W3085657245 creator A5005908618 @default.
• W3085657245 creator A5014011459 @default.
• W3085657245 creator A5018592613 @default.
• W3085657245 creator A5021274228 @default.
• W3085657245 creator A5033811992 @default.
• W3085657245 creator A5043656051 @default.
• W3085657245 creator A5048440121 @default.
• W3085657245 creator A5059134399 @default.
• W3085657245 creator A5064285955 @default.
• W3085657245 creator A5066560929 @default.
• W3085657245 creator A5070370737 @default.
• W3085657245 creator A5086668079 @default.
• W3085657245 creator A5091547828 @default.
• W3085657245 date "2020-09-16" @default.
• W3085657245 modified "2023-10-13" @default.
• W3085657245 title "Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation" @default.
• W3085657245 cites W1415829101 @default.
• W3085657245 cites W1484293540 @default.
• W3085657245 cites W1562405218 @default.
• W3085657245 cites W1781634362 @default.
• W3085657245 cites W1796660362 @default.
• W3085657245 cites W1910312434 @default.
• W3085657245 cites W1992039743 @default.
• W3085657245 cites W1998794592 @default.
• W3085657245 cites W2010070416 @default.
• W3085657245 cites W2017000328 @default.
• W3085657245 cites W2019057404 @default.
• W3085657245 cites W2019511770 @default.
• W3085657245 cites W2021378114 @default.
• W3085657245 cites W2039334806 @default.
• W3085657245 cites W2040852160 @default.
• W3085657245 cites W2044303805 @default.
• W3085657245 cites W2054204373 @default.
• W3085657245 cites W2055553511 @default.
• W3085657245 cites W2061878111 @default.
• W3085657245 cites W2064816747 @default.
• W3085657245 cites W2074425311 @default.
• W3085657245 cites W2086990980 @default.
• W3085657245 cites W2118515712 @default.
• W3085657245 cites W2120756704 @default.
• W3085657245 cites W2127080762 @default.
• W3085657245 cites W2128541003 @default.
• W3085657245 cites W2131006960 @default.
• W3085657245 cites W2160646954 @default.
• W3085657245 cites W2169530433 @default.
• W3085657245 cites W2296458069 @default.
• W3085657245 cites W2379365975 @default.
• W3085657245 cites W2404301843 @default.
• W3085657245 cites W2559537906 @default.
• W3085657245 cites W2617820327 @default.
• W3085657245 cites W2740316591 @default.
• W3085657245 cites W2789625486 @default.
• W3085657245 cites W2800808649 @default.
• W3085657245 cites W49583968 @default.
• W3085657245 doi "https://doi.org/10.1182/bloodadvances.2020002074" @default.
• W3085657245 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7509859" @default.
• W3085657245 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32936907" @default.
• W3085657245 hasPublicationYear "2020" @default.
• W3085657245 type Work @default.
• W3085657245 sameAs 3085657245 @default.
• W3085657245 citedByCount "19" @default.
• W3085657245 countsByYear W30856572452021 @default.
• W3085657245 countsByYear W30856572452022 @default.
• W3085657245 countsByYear W30856572452023 @default.
• W3085657245 crossrefType "journal-article" @default.
• W3085657245 hasAuthorship W3085657245A5005908618 @default.
• W3085657245 hasAuthorship W3085657245A5014011459 @default.
• W3085657245 hasAuthorship W3085657245A5018592613 @default.
• W3085657245 hasAuthorship W3085657245A5021274228 @default.
• W3085657245 hasAuthorship W3085657245A5033811992 @default.
• W3085657245 hasAuthorship W3085657245A5043656051 @default.
• W3085657245 hasAuthorship W3085657245A5048440121 @default.
• W3085657245 hasAuthorship W3085657245A5059134399 @default.
• W3085657245 hasAuthorship W3085657245A5064285955 @default.
• W3085657245 hasAuthorship W3085657245A5066560929 @default.
• W3085657245 hasAuthorship W3085657245A5070370737 @default.
• W3085657245 hasAuthorship W3085657245A5086668079 @default.
• W3085657245 hasAuthorship W3085657245A5091547828 @default.
• W3085657245 hasBestOaLocation W30856572451 @default.
• W3085657245 hasConcept C104317684 @default.
• W3085657245 hasConcept C126322002 @default.
• W3085657245 hasConcept C143998085 @default.
• W3085657245 hasConcept C150194340 @default.
• W3085657245 hasConcept C185592680 @default.
• W3085657245 hasConcept C190727270 @default.
• W3085657245 hasConcept C2777408962 @default.
• W3085657245 hasConcept C2778305200 @default.
• W3085657245 hasConcept C2778729363 @default.
• W3085657245 hasConcept C2779695342 @default.
• W3085657245 hasConcept C2780007613 @default.
• W3085657245 hasConcept C2780225316 @default.
• W3085657245 hasConcept C2780235182 @default.
• W3085657245 hasConcept C2780366003 @default.
• W3085657245 hasConcept C2911091166 @default.
• W3085657245 hasConcept C55493867 @default.
• W3085657245 hasConcept C64927066 @default.

• next